H1 2024 RNA LANDSCAPE REVIEW

Explore the most detailed analysis of the RNA landscape with our exclusive two-part series. This comprehensive review offers a complete overview of the drug landscape, key clinical trial advancements, and critical regulatory milestones, culminating in an in-depth look at emerging trends and market insights. Powered by Beacon data, this series is an invaluable resource for industry professionals looking to stay ahead in this rapidly evolving sector.

Download your sample copy today for a thorough examination of the current market, a summary of H1 2024 regulatory developments, and expert insights into the future of the RNA field.

The RNA H1 Drug Landscape in 2024

Download Here

The RNA H1 Trial Landscape in 2024

Coming Soon

About the report

The analysis includes:

- The Drug and Trial Landscape – An analysis of all 4300+ drugs and 2000+ trials on Beacon RNA by modality, trial status, disease indication and more, providing a comprehensive overview of the entire RNA landscape.
- Current Market and Development Challenges – A breakdown of which challenges the RNA space is facing in particular
- The Deals and Companies Landscape – Insight into the commercial landscape, using the new Deals and Companies dataset, including deal types and company location, and a look at the regulatory updates and future of the space based on data availability.

Find out more

Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.

With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.

Discover a database tailored to your needs